Ceritinib vs Ensartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Non-Small Cell Lung Cancer
Shared mechanism: ALK · full Non-Small Cell Lung Cancer pipeline
Ceritinib
Marketed by Novartis
NCT01828099 · Phase 3 · completed
The trial was randomized and actively controlled, with 189 patients assigned to ceritinib and 187 to chemotherapy, but treatment was open-label rather than double-blind. Its clinical primary endpoint, progression-free survival assessed by an independent review committee, was met: median progression-free survival was 16.6 versus 8.1 months, with hazard ratio 0.55 (95% CI 0.42–0.73; p<0.001).
Next expected readout: December 2026 · NCT02321501 (registry estimate)
Reported efficacy
Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Progression Free Survival (PFS) by Blinded Independent Review Committee (BIRC) (From the date of randomization to the date of first radiologically documented disease progression or death due to any cause, up to approximately 34 months): Ceritinib 16.6 Months (95% CI 12.6 to 27.2) vs Chemotherapy 8.1 Months (95% CI 5.8 to 11.1) (met)
Result source: NCT01828099
Ensartinib · Ensacove
Marketed by Xcovery Holdings and partners
NCT02767804 · Phase 3 · active, not recruiting
This was a randomized, phase 3, active-controlled trial with 290 patients comparing ensartinib to crizotinib, using progression-free survival (a hard clinical endpoint) as the primary measure, and the trial met its primary endpoint with a large, statistically significant improvement favoring ensartinib. However, the study was open-label (no blinding of patients or investigators), which limits confidence in outcome assessments despite the use of independent radiology review, so the evidence is graded as solid but not the highest tier.
Next expected readout: February 2027 · NCT05241028 (registry estimate)
Reported efficacy
Progression-free survival (PFS) (36 months): eXalt3 (NCT02767804), primary endpoint PFS: ensartinib median PFS 25.8 months vs crizotinib 12.7 months; HR 0.51 (95% CI 0.35-0.72); p<.001. (met)
Result source: NCT02767804
Results for Non-Small Cell Lung Cancer
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Ceritinib | Ensartinib |
|---|---|---|
| PFS, median | 16.6 vs 8.1vs ChemotherapyNCT0182809910 other results
| —Trial running · NCT06955325 |
| OS, median | 62.9 vs 40.7vs ChemotherapyNCT018280995 other results
| —Trial running · NCT06955325 |
| ORR | 72.5% vs 26.7%vs ChemotherapyNCT0182809912 other results
| —Trial running · NCT06955325 |
| Duration of response, median | 23.9 vs 11.1vs ChemotherapyNCT0182809912 other results
| —Trial running · NCT06955325 |
PFS, median
- Ceritinib
- 16.6 vs 8.1vs ChemotherapyNCT01828099
10 other results
- 5.4 vs 1.6 NCT01828112
- 16.8 vs 7.2 NCT01828099
- 6.2 vs 1.6 NCT01828112
- 5.8 NCT01685060
- 7.4 NCT01685060
- 15.2 NCT01283516
- 19.3 NCT01283516
- 7.2 NCT02040870
- 3.8 NCT02040870
- 3.7 NCT02450903
- Ensartinib
- —Trial running · NCT06955325
OS, median
- Ceritinib
- 62.9 vs 40.7vs ChemotherapyNCT01828099
5 other results
- 17.7 vs 20.1 NCT01828112
- 15.6 NCT01685060
- 51.3 NCT01685138
- 17.5 NCT02040870
- 17.3 NCT02450903
- Ensartinib
- —Trial running · NCT06955325
ORR
- Ceritinib
- 72.5% vs 26.7%vs ChemotherapyNCT01828099
12 other results
- 73.5% vs 33.2% NCT01828099
- 40.9% vs 6.9% NCT01828112
- 44.3% vs 6.9% NCT01828112
- 40.7% NCT01685060
- 67.7% NCT01685138
- 25% NCT02450903
- 35.7% NCT01685060
- 73.5% NCT01283516
- 65.1% NCT01283516
- 63.7% NCT01685138
- 41.7% NCT02040870
- 32% NCT02040870
- Ensartinib
- —Trial running · NCT06955325
Duration of response, median
- Ceritinib
- 23.9 vs 11.1vs ChemotherapyNCT01828099
12 other results
- 22.6 vs 9.8 NCT01828099
- 7.6 vs 10.4 NCT01828112
- 6.7 vs 8.3 NCT01828112
- 10.6 NCT01685060
- 12.9 NCT01685060
- 14.2 NCT01283516
- 21.8 NCT01283516
- 24 NCT01685138
- 27.3 NCT01685138
- 7.5 NCT02040870
- 9.2 NCT02040870
- 6.3 NCT02450903
- Ensartinib
- —Trial running · NCT06955325
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. Ceritinib: 4 of 4 rows · Ensartinib: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Ceritinib | Ensartinib |
|---|---|---|
| Dropout rate | n/a: no completion milestonea NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more resultsn/a: no completion milestoneCeritinib NCT01828112 · Phase 3 · monotherapy —Ceritinib (On-treatment) NCT01828112 · Phase 3 n/a: no completion milestone750 mg NCT01283516 · Phase 1 n/a: no completion milestone700 mg NCT01283516 · Phase 1 n/a: no completion milestone600 mg NCT01283516 · Phase 1 n/a: no completion milestone500 mg NCT01283516 · Phase 1 n/a: no completion milestone400 mg NCT01283516 · Phase 1 n/a: no completion milestone300 mg NCT01283516 · Phase 1 n/a: no completion milestone200 mg NCT01283516 · Phase 1 n/a: no completion milestone100 mg NCT01283516 · Phase 1 n/a: no completion milestone50 mg NCT01283516 · Phase 1 n/a: no completion milestone NCT02450903 · Phase 2 · registry result, not featured evidence 74.2%LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence n/a: no completion milestone750 mg NCT01685060 · Phase 2 · registry result, not featured evidence n/a: no completion milestone NCT02040870 · Phase 1/2 · registry result, not featured evidence | 0%225 mgb NCT01625234 · Phase 1/2 show 7 more results0%225 mg NCT01625234 · Phase 1/2 0%250 mg NCT01625234 · Phase 1/2 0%200 mg NCT01625234 · Phase 1/2 0%100 mg NCT01625234 · Phase 1/2 0%50 mg NCT01625234 · Phase 1/2 0%25 mg NCT01625234 · Phase 1/2 n/a: no completion milestone200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Discontinued due to AEs | 12.7%a NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more results6.1%Ceritinib NCT01828112 · Phase 3 · monotherapy —Ceritinib (On-treatment) NCT01828112 · Phase 3 11%750 mg NCT01283516 · Phase 1 0%700 mg NCT01283516 · Phase 1 20%600 mg NCT01283516 · Phase 1 0%500 mg NCT01283516 · Phase 1 0%400 mg NCT01283516 · Phase 1 0%300 mg NCT01283516 · Phase 1 0%200 mg NCT01283516 · Phase 1 0%100 mg NCT01283516 · Phase 1 0%50 mg NCT01283516 · Phase 1 15% NCT02450903 · Phase 2 · registry result, not featured evidence 14.5%LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 8.6%750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 6.8% NCT02040870 · Phase 1/2 · registry result, not featured evidence | —225 mgb NCT01625234 · Phase 1/2 show 7 more results—225 mg NCT01625234 · Phase 1/2 —250 mg NCT01625234 · Phase 1/2 —200 mg NCT01625234 · Phase 1/2 —100 mg NCT01625234 · Phase 1/2 —50 mg NCT01625234 · Phase 1/2 —25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Serious AEs | 49.2%a NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 17 more results—Ceritinib NCT01828112 · Phase 3 · monotherapy 49.6%Ceritinib (On-treatment) NCT01828112 · Phase 3 56.9%750 mg NCT01283516 · Phase 1 60%700 mg NCT01283516 · Phase 1 70%600 mg NCT01283516 · Phase 1 40%500 mg NCT01283516 · Phase 1 50%400 mg NCT01283516 · Phase 1 33.3%300 mg NCT01283516 · Phase 1 33.3%200 mg NCT01283516 · Phase 1 50%100 mg NCT01283516 · Phase 1 0%50 mg NCT01283516 · Phase 1 45% NCT02450903 · Phase 2 · registry result, not featured evidence —LDK378 (Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence 40.3%LDK378 Ceritinib) NCT01685138 · Phase 2 · registry result, not featured evidence 47.9%750 mg NCT01685060 · Phase 2 · registry result, not featured evidence —750 mg NCT01685060 · Phase 2 · registry result, not featured evidence 35% NCT02040870 · Phase 1/2 · registry result, not featured evidence | 50%225 mgb NCT01625234 · Phase 1/2 show 7 more results43.6%225 mg NCT01625234 · Phase 1/2 50%250 mg NCT01625234 · Phase 1/2 54.5%200 mg NCT01625234 · Phase 1/2 40%100 mg NCT01625234 · Phase 1/2 33.3%50 mg NCT01625234 · Phase 1/2 25%25 mg NCT01625234 · Phase 1/2 50%200 mg NCT02898116 · Phase 1/2 · registry result, not featured evidence |
| Most frequent reported AEs | a diarrhoea 84.7% nausea 68.8% vomiting 67.2% NCT01828099 · Phase 3 · monotherapy · Non-Small Cell Lung Cancer · phase 3 show 14 more resultsdiarrhoea 85.5% nausea 78.2% vomiting 71.8% NCT01685138 · Phase 2 · registry result, not featured evidence 750 mg diarrhoea 82.1% nausea 82.1% vomiting 65.7% NCT01685060 · Phase 2 · registry result, not featured evidence diarrhoea 74.8% vomiting 61.2% alanine aminotransferase increased 59.2% NCT02040870 · Phase 1/2 · registry result, not featured evidence | show 7 more results200 mg hypoalbuminaemia 100% anaemia 50% arthralgia 50% NCT02898116 · Phase 1/2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for 17 of these studies.
- bPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Ceritinib
show 3 more results
show 1 more result
show 3 more results
show 3 more results
show 3 more results
show 3 more results
show 8 more results
show 8 more results
show 6 more results
+ 6 further endpoints in the CSV export.
Ensartinib
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Ceritinib's landscape · Ensartinib's landscape